Catechins containing a galloyl moiety as potential anti-HIV-1 compounds

Drug Discovery Today

Volumn 17, Issue 11-12, 2012, Pages 630-635

  Zhao, Yali ^a   Jiang, Fan ^a   Liu, Ping ^a   Chen, Wei ^a   Yi, Kejia ^b  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b Beijing Science Technology and Management College   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CASEIN KINASE II; CATECHIN; GLYCOPROTEIN GP 120; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NITRIC OXIDE SYNTHASE; RNA DIRECTED DNA POLYMERASE; VIRUS FUSION PROTEIN;

ANTIVIRAL ACTIVITY; CD4+ T LYMPHOCYTE; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG TARGETING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; NONHUMAN; PROTEIN BINDING; REVIEW; SEXUAL TRANSMISSION; VIRUS TRANSMISSION;

ANTI-HIV AGENTS; CATECHIN; DRUG DISCOVERY; HIV INFECTIONS; HIV-1; HUMANS; MOLECULAR STRUCTURE;

EID: 84862805737     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2012.02.015     Document Type: Review

References (62)

1. A. Taege Seek and treat: HIV update 2011 Cleve. Clin. J. Med. 78 2011 95 100
2. P. Cos Plant-derived leading compounds for chemotherapy of human immunodeficiency virus (HIV) infection - an update (1998-2007) Planta Med. 74 2008 1323 1337
3. R.J. Pomerantz, and D.L. Horn Twenty years of therapy for HIV-1 infection Nat. Med. 9 2003 867 873
4. E.D. Clercq Antiretroviral drugs Curr. Opin. Pharmacol. 10 2010 507 515
5. N. Mehta, and M. Reilly Atherosclerotic cardiovascular disease risk in the HAART-treated HIV-1 population HIV Clin. Trials 6 2005 5 24
6. A.F. Poon Transmitted drug resistance in the CFAR network of integrated clinical systems cohort: prevalence and effects on pre-therapy CD4 and viral load PLoS ONE 6 2011 e21189
7. S. Liu Theaflavin derivatives in black tea and catechin derivatives in green tea inhibit HIV-1 entry by targeting gp41 Biochim. Biophys. Acta 1723 2005 270 281
8. C.L. Nance Preclinical development of the green tea catechin, epigallocatechin gallate, as an HIV-1 therapy J. Allergy Clin. Immunol. 123 2009 459 465
9. J.M. Song, and B.L. Seong Tea catechins as a potential alternative anti-infectious agent Expert Rev. Anti Infect. Ther. 5 2007 497 506
10. C. Cabrera Beneficial effects of green tea - a review J. Am. Coll. Nutr. 25 2006 79 99
11. X. Wang The galloyl moiety of green tea catechins is the critical structural feature to inhibit fatty-acid synthase Biochem. Pharmacol. 66 2003 2039 2047
12. I. Ikeda Multifunctional effects of green tea catechins on prevention of the metabolic syndrome Asia Pac. J. Clin. Nutr. 17 Suppl. 1 2008 273 274
13. C. Karasu Glycoxidative stress and cardiovascular complications in experimentally-induced diabetes: effects of antioxidant treatment Open Cardiovasc. Med. J. 4 2010 240 256
14. T.B. Kryston Role of oxidative stress and DNA damage in human carcinogenesis Mutat. Res. 711 2011 193 201
15. S. Coaccioli Oxidant/antioxidant status in patients with chronic HIV infection Clin. Ter. 161 2010 55 58
16. W.Y. Feng Pycnogenol, a procyanidin-rich extract from French maritime pine, inhibits intracellular replication of HIV-1 as well as its binding to host cells Jpn. J. Infect. Dis. 61 2008 279 285
17. C.S. Yang Cancer prevention by tea: animal studies, molecular mechanisms and human relevance Nat. Rev. Cancer 9 2009 429 439
18. K. Yamaguchi Inhibitory effects of (-)-epigallocatechin gallate on the life cycle of human immunodeficiency virus type 1 (HIV-1) Antiviral Res. 53 2002 19 34
19. I. Hauber The main green tea polyphenol epigallocatechin-3-gallate counteracts semen-mediated enhancement of HIV infection Proc. Natl Acad. Sci. U. S. A. 106 2009 9033 9038
20. M.P. Williamson Epigallocatechin gallate, the main polyphenol in green tea, binds to the T-cell receptor, CD4: potential for HIV-1 therapy J. Allergy Clin. Immunol. 118 2006 1369 1374
21. K. Kawai Epigallocatechin gallate, the main component of tea polyphenol, binds to CD4 and interferes with gp120 binding J. Allergy Clin. Immunol. 112 2003 951 957
22. L.M. Tillekeratne Simplified catechin-gallate inhibitors of HIV-1 reverse transcriptase Bioorg. Med. Chem. Lett. 11 2001 2763 2767
23. L.M. Tillekeratne Differential inhibition of polymerase and strand-transfer activities of HIV-1 reverse transcriptase Bioorg. Med. Chem. Lett. 12 2002 525 528
24. F. Jiang The evaluation of catechins that contain a galloyl moiety as potential HIV-1 integrase inhibitors Clin. Immunol. 137 2010 347 356
25. E. Melgarejo Targeting of histamine producing cells by EGCG: a green dart against inflammation? J. Physiol. Biochem. 66 2010 265 270
26. E. Haneda Biochemical characterization of casein kinase II as a protein kinase responsible for stimulation of HIV-1 protease in vitro Biochem. Biophys. Res. Commun. 275 2000 434 439
27. U. Ullmann Plasma-kinetic characteristics of purified and isolated green tea catechin epigallocatechin gallate (EGCG) after 10 days repeated dosing in healthy volunteers Int. J. Vitam. Nutr. Res. 74 2004 269 278
28. U. Ullmann A single ascending dose study of epigallocatechin gallate in healthy volunteers J. Int. Med. Res. 31 2003 88 101
29. H.H. Chow Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals Clin. Cancer Res. 9 2003 3312 3319
30. J.S. Olsen Amyloid-binding small molecules efficiently block SEVI (semen-derived enhancer of virus infection)- and semen-mediated enhancement of HIV-1 infection J. Biol. Chem. 285 2010 35488 35496
31. K.A. Kim Semen-mediated enhancement of HIV infection is donor-dependent and correlates with the levels of SEVI Retrovirology 7 2010 55
32. Q.Y. Zhu Stability of green tea catechins J. Agric. Food Chem. 45 1997 4624 4628
33. M.L. Greenberg, and N. Cammack Resistance to enfuvirtide, the first HIV fusion inhibitor J. Antimicrob. Chemother. 54 2004 333 340
34. C.A. Janeway Jr. CD4+ T cells: specificity and function Immunol. Rev. 101 1988 39 80
35. L. Gray Conformational alterations in the CD4 binding cavity of HIV-1 gp120 influencing gp120-CD4 interactions and fusogenicity of HIV-1 envelopes derived from brain and other tissues Retrovirology 8 2011 42
36. A. Schweizer CD4-specific designed ankyrin repeat proteins are novel potent HIV entry inhibitors with unique characteristics PLoS Pathog. 4 2008 e1000109
37. H. Wu Kinetic and structural analysis of mutant CD4 receptors that are defective in HIV gp120 binding Proc. Natl Acad. Sci. U. S. A. 93 1996 15030 15035
38. R. Pejchal, and I.A. Wilson Structure-based vaccine design in HIV: blind men and the elephant? Curr. Pharm. Des. 16 2010 3744 3753
39. D.C. Chan Core structure of gp41 from the HIV envelope glycoprotein Cell 89 1997 263 273
40. M. Gotte Reverse transcriptase in motion: conformational dynamics of enzyme-substrate interactions Biochim. Biophys. Acta 1804 2010 1202 1212
41. P.S. Moore, and C. Pizza Observations on the inhibition of HIV-1 reverse transcriptase by catechins Biochem. J. 288 1992 717 719
42. Y. Pommier Integrase inhibitors to treat HIV/AIDS Nat. Rev. Drug Discov. 4 2005 236 248
43. M. Lataillade, and M.J. Kozal The hunt for HIV-1 integrase inhibitors AIDS Patient Care STDS 20 2006 489 501
44. J.D. Croxtall Raltegravir Drugs 68 2008 131 138
45. F. Volonte Optimizing HIV-1 protease production in Escherichia coli as fusion protein Microb. Cell Fact. 10 2011 53
46. C. Ma Inhibitory effects on HIV-1 protease of constituents from the wood of Xanthoceras sorbifolia J. Nat. Prod. 63 2000 238 242
47. D. Blond Nitric oxide synthesis enhances human immunodeficiency virus replication in primary human macrophages J. Virol. 74 2000 8904 8912
48. F. Zwicker A specific inhibitor of protein kinase CK2 delays gamma-H2Ax foci removal and reduces clonogenic survival of irradiated mammalian cells Radiat. Oncol. 6 2011 15
49. J. Friborg Functional analysis of the phosphorylation sites on the human immunodeficiency virus type 1 Vpu protein J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 8 1995 10 22
50. D. Sargeant HIVToolbox, an integrated web application for investigating HIV PLoS ONE 6 2011 e20122
51. F. Meggio HIV-1 Rev transactivator: a beta-subunit directed substrate and effector of protein kinase CK2 Mol. Cell. Biochem. 227 2001 145 151
52. A. Ali, and F. Alqurainy Activities of Antioxidants in Plants under Environmental Stress 1st edn 2006 Transworld Research Network
53. W.Y. Feng Metabolism of green tea catechins: an overview Curr. Drug Metab. 7 2006 755 809
54. M. Schantz Metabolism of green tea catechins by the human small intestine Biotechnol. J. 5 2010 1050 1059
55. H.H. Chow Effects of repeated green tea catechin administration on human cytochrome P450 activity Cancer Epidemiol. Biomarkers Prev. 15 2006 2473 2476
56. F. Maggiolo Efavirenz: a decade of clinical experience in the treatment of HIV J. Antimicrob. Chemother. 64 2009 910 928
57. A.Y. Dagnra High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lomé, Togo J. Int. AIDS Soc. 14 2011 1 6
58. F. Zhou Expenditures for the care of HIV-infected patients in rural areas in China's antiretroviral therapy programs BMC Med. 9 2011 6
59. A. Dube Chitosan nanoparticles enhance the intestinal absorption of the green tea catechins (+)-catechin and (-)-epigallocatechin gallate Eur. J. Pharm. Sci. 41 2010 219 225
60. A. Smith Nanolipidic particles improve the bioavailability and alpha-secretase inducing ability of epigallocatechin-3-gallate (EGCG) for the treatment of Alzheimer's disease Int. J. Pharm. 389 2010 207 212
61. A.W. Schuttelkopf, and D.M. van Aalten PRODRG: a tool for high-throughput crystallography of protein-ligand complexes Acta Crystallogr. D Biol. Crystallogr. 60 2004 1355 1363
62. Y. Goldgur Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design Proc. Natl Acad. Sci. U. S. A. 96 1999 13040 13043